An early gene therapy trial reported maintenance of vision, reduced retinal inflammation, and detectable therapeutic protein levels 9 months after treatment for age-related macular degeneration.
Presented at ASRS 2023, the results showed clinically meaningful reductions in anti-VEGF treatment burden at all dose levels of intravitreal 4D-150 in patients with a high anti-VEGF need.
Stonegate Healthcare Reviews Retinitis Pigmentosa streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.